We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microfluidic Device Brings Single-Cell Technology to Bedside

By LabMedica International staff writers
Posted on 06 Mar 2018
Image: The microfluidic control instrument performing a Drop-seq run (Photo courtesy of the New York Genome Center).
Image: The microfluidic control instrument performing a Drop-seq run (Photo courtesy of the New York Genome Center).
The complex architecture and associated higher-order function of human tissues relies on functionally and molecularly diverse cell populations. Defining the cellular subsets found in pathologic tissues provides insights into disease etiology and treatment options.

Traditional methods such as flow cytometry, which require a priori knowledge of cell type-specific markers, have begun to define this landscape, but fall short in comprehensively identifying cellular states in a tissue, with particular difficulty detecting extremely rare subpopulations.

Scientists at the New York Genome Center (New York, NY, USA) and their colleagues have facilitated broad access to single-cell sequencing by developing a 3D-printed, portable and low-cost microfluidic controller. They adapted this device to perform massively parallel single-cell RNA-seq (Drop-seq), observing metrics and performance that are indistinguishable from a study level Drop-seq setup.

The group used the instrument to profile joint synovial tissue from rheumatoid arthritis (RA) patients. RA is an autoimmune disease that affects 1% of the population and is associated with painful swelling in the joints. The precise cause of RA is undetermined and muddled by the diversity of cells found in the swollen joints of patients. The portability of the controller permitted patient samples to be processed on-site and immediately after surgery, minimizing handling and transport to optimize sample quality. The team collected samples from five RA patients totaling 20,387 cells and looked at the individual gene expression patterns for each cell.

By analyzing the complete dataset and searching for clusters of similar cells, the scientists identified 13 groups, representing both infiltrating immune and inflamed stromal populations. Of particular interest were distinct groups of fibroblasts with strikingly different gene expression patterns. They were able to validate the presence of these multiple groups using BD FACSAria II flow cytometry sorter, and discovered that they exhibited distinct localization patterns with the joint tissue as well. The instrument processes 1 mL of cells at a concentration of 150–200 cells/µL in about 30 minutes, generating over one million droplets at a generation rate of approximately 700 Hz.

Instructions and assembly manuals for the instrument can be found online at the popular microfluidics repository Metafluidics. The 3D-printed custom device, which, along with its electronic and pneumatic components, can be easily obtained and assembled for a total cost of about USD 600, a fraction of the cost of comparable commercial systems. The device occupies a small footprint as well, not much larger than a tissue box.

William Stephenson PhD, a Senior Research Engineer, and lead author of the study, said, “Most commercial microfluidic instruments are very costly; as a result, not every lab has access to exciting technology for single-cell analysis. We designed the instrument to perform droplet microfluidics and in particular Drop-seq, a massively parallel technology for single cell RNA-sequencing.” The study was published on February 23, 2018, in the journal Nature Communications.

Related Links:
New York Genome Center

New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL